Skip to main content

Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Treatment Research Study Available to those with Non-Alcoholic Fatty Liver Disease

a family of three smiling

a man and a woman smiling

Are you looking for a treatment for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)? Researchers at the National Institutes of Health seek volunteers to participate in a research study. For 30 weeks, participants will receive a medication called semaglutide (typically used for Type 2 diabetes), aiming to improve their liver disease and help them lose weight. The study hopes to better understand liver damage and its treatment in people with these conditions.

To Join our Study:

  • You must be at least 18-year-old.
  • You must be diagnosed or suspected to have non-alcoholic fatty liver disease or nonalcoholic steatohepatitis.
  • You must not be pregnant or breastfeeding.

Participation Details:

  • You will have an initial screening visit. Our team will collect your medical history, provide a physical exam, request blood work and an abdominal ultrasound. If you are eligible to continue, you will be scheduled for additional visits and admissions.
  • All participants will receive medications and medical procedures at no cost and compensation will be provided.

Study Location: The NIH Clinical Center, America's Research Hospital, located on the Metro red line (Medical Center stop) in Bethesda, MD.

For more information:
NIH Clinical Center Office of Patient Recruitment
1-800-411-1222 (refer to study # 19-DK-0072)
(TTY users dial 7-1-1)
Se habla español
Email: ccopr@nih.gov

Or go online:
https://go.usa.gov/xmJ8q

Department of Health and Human Services
National Institutes of Health Clinical Center
National Institute of Diabetes and Digestive and Kidney Diseases